![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Neurology Product Name: AD101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Societal CDMO
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Neurology Product Name: AD101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AmyriAD
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement June 01, 2022
Details:
This agreement covers the exchange of clinical and nonclinical trial information related to COVID-19 treatment using the repurposed Raloxifene molecule developed by five research organisations from the EU and South Korea.
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CINECA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 18, 2020
Details:
A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate4Cov’s guidelines.
Lead Product(s): Raloxifene Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020